The size of outpatient prescriptions of Montelukast for asthma and allergic rhinitis has increased by 21% in a year. The market, which had been stagnant for the past two years due to the COVID-19 incident and side effect issues, seems to be recovering from its previous year's prescription performance this year. It was found that the impurity negative factor that occurred at the beginning of the year also did not have a significant impact on the market recovery. According to UBIST, a pharmaceutical market research institute on the 9th, the outpatient RX in the Montelukast asthma treatment market in the third quarter of this year was 80.5 billion won. It increased by 18% compared to 68 billion won in the same period last y